Les meilleurs podcasts BioCentury (2024)

1
Ep. 63 - Day One's Jeremy Bender: Building Pediatric Oncology from the Ground Up 32:27

5d ago32:27

32:27

Pediatric cancer drug development is difficult: it requires high levels of safety, involves parents as well as the patients, and has small populations that can make it difficult to achieve the revenues that reward the investment. Squaring that circle, according to Day One Biopharmaceuticals CEO Jeremy Bender, is not impossible, but takes a dedicate…

1
Ep. 62 - Rick Bright: Navigating the Avian Flu Threat 40:22

19d ago40:22

40:22

The U.S. is experiencing events that are either the first stages of a widespread avian influenza outbreak or a fire drill that will show how well the nation is prepared for an outbreak. The U.S. has not stepped up to meet the challenge, Rick Bright, the former director of BARDA, told BioCentury. In an interview with The BioCentury Show's Steve Usdi…

1
Ep. 61 - Vas Narasimhan: How New Data Fit Novartis’ Growth Plan 32:11

1M ago32:11

32:11

Differentiating on tolerability, raising the bar for efficacy and concentrating small molecule development on indications with minimal IRA exposure are all pieces of Novartis CEO Vasant Narasimhan’s strategy to break into the top pharmas by U.S. sales. Two data readouts this week — one for CML drug Scemblix at ASCO and one for inflammatory disease …

1
Ep. 60 - JMM John Maraganore: A higher bar for investment is a credit to biotech 36:00

1M ago36:00

36:00

“The bar has gotten higher because science has gotten so much better,” John Maraganore says on the latest BioCentury Show. Reflecting on the capital markets and the state of innovation, the founder and former CEO of Alnylam painted a picture of a robust ecosystem fueled by sprawling innovation, where the higher scrutiny by investors will serve the …

1
Ep. 59 - Derek Lowe Unplugged: AI; Biosecure; FDA, Abortion & SCOTUS; and more 32:09

2M ago32:09

32:09

“I’m a short-term pessimist and a long-term optimist” about the potential for AI to transform drug development, Derek Lowe, author of the In the Pipeline blog, told BioCentury Washington Editor Steve Usdin on the latest BioCentury Show. Lowe's skepticism about claims that AI will rapidly transform the field is driven by a belief that the “problems …

1
Ep. 57 - BMS's Robert Plenge: Causal biology is the North Star of R&D 31:17

2M ago31:17

31:17

This is a previously recorded episode of The BioCentury Show. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes. Within the framework of target, modality and path to clinic, causal biology is the axis along which Head of Research Robert Plenge is building and prosecuting r…

1
Ep. 58 - Ysios' Karen Wagner: How Europe's Biotechs Can Rise Above the Noise 30:54

2M ago30:54

30:54

It sounds obvious, but still needs saying, says Ysios Capital's Karen Wagner. “How do you rise above the noise? By having the most spectacular data.” In conversation with Editor in Chief Simone Fishburn on The BioCentury Show, Wagner discussed the theme of the upcoming Bio€quity Europe conference — rising above the noise: in a sea of competition wh…

1
Ep. 53 - Bob Nelsen on AI, China and the IRA 35:26

3M ago35:26

35:26

This is a previously recorded episode of The BioCentury Show. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes. In a wide-ranging conversation with BioCentury, Bob Nelsen, co-founder and managing director of Arch Venture Partners, said he is excited by the potential for A…

1
Ep. 54 - Arthur Caplan: Lessons From a Compassionate Use Firestorm 30:52

3M ago30:52

30:52

This is a previously recorded episode of The BioCentury Show. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes. On the tenth anniversary of a viral media campaign for access to an unapproved drug that extended a boy’s life, bioethicist Arthur Caplan reflected in an interv…

1
Ep. 55 - Bruce Booth: Biotech Benefiting from Belt-Tightening 32:10

3M ago32:10

32:10

This is a previously recorded episode of The BioCentury Show. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes. Atlas Venture’s Bruce Booth believes the belt-tightening by biotechs in the past few years will presage a better financing outlook for companies, but the ripple…

1
Ep. 56 - BIO’s John Crowley on the Biosecure Act 36:55

3M ago36:55

36:55

This is a previously recorded episode of The BioCentury Show. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes. BIO CEO John Crowley believes that biotech is part of a “great global rivalry” between the U.S. and China. The role of biotech in determining the outcome of thi…

1
Ep. 52 - Khoo Shih on Scaling Singapore Biotech 31:27

3M ago31:27

31:27

This is a previously recorded episode of The BioCentury Show. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes. Success for the Singapore biotech project will take a global network, one which Khoo Shih and other prominent drivers of the local ecosystem are keen to leverag…

Podcasts qui valent la peine d'être écoutés

BioCentury Podcasts

Podcasts qui valent la peine d'être écoutés

1
The BioCentury Show

BioCentury

1
Ep. 63 - Day One's Jeremy Bender: Building Pediatric Oncology from the Ground Up 32:27

1
Ep. 62 - Rick Bright: Navigating the Avian Flu Threat 40:22

1
Ep. 61 - Vas Narasimhan: How New Data Fit Novartis’ Growth Plan 32:11

1
Ep. 60 - JMM John Maraganore: A higher bar for investment is a credit to biotech 36:00

1
Ep. 59 - Derek Lowe Unplugged: AI; Biosecure; FDA, Abortion & SCOTUS; and more 32:09

1
Ep. 57 - BMS's Robert Plenge: Causal biology is the North Star of R&D 31:17

1
Ep. 58 - Ysios' Karen Wagner: How Europe's Biotechs Can Rise Above the Noise 30:54

1
Ep. 53 - Bob Nelsen on AI, China and the IRA 35:26

1
Ep. 54 - Arthur Caplan: Lessons From a Compassionate Use Firestorm 30:52

1
Ep. 55 - Bruce Booth: Biotech Benefiting from Belt-Tightening 32:10

1
Ep. 56 - BIO’s John Crowley on the Biosecure Act 36:55

1
Ep. 52 - Khoo Shih on Scaling Singapore Biotech 31:27

Guide de référence rapide